However, our current work shows that GM-CSF preferentially induces Th2-polarizing GMiDCs in the spleen, which likely limits anti-cancer immunity (73), although GMiDCs can also boost Th1 responses better than cDC subsets. The gene discussed is CSF2; the disease is cancer.